BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27915441)

  • 1. Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?
    Lobo J; Pinto C; Freitas M; Pinheiro M; Vizcaino R; Oliva E; Teixeira MR; Jerónimo C; Bartosch C
    Virchows Arch; 2017 Mar; 470(3):347-352. PubMed ID: 27915441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case.
    Kientz C; Prieur F; Clemenson A; Joly MO; Stachowicz ML; Auclair J; Attignon V; Schiappa R; Wang Q
    Fam Cancer; 2020 Jan; 19(1):11-14. PubMed ID: 31745674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
    Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
    Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Germline
    Klančar G; Blatnik A; Šetrajčič Dragoš V; Vogrič V; Stegel V; Blatnik O; Drev P; Gazič B; Krajc M; Novaković S
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32197529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline mutations in PMS2 and MLH1 in individuals with solitary loss of PMS2 expression in colorectal carcinomas from the Colon Cancer Family Registry Cohort.
    Rosty C; Clendenning M; Walsh MD; Eriksen SV; Southey MC; Winship IM; Macrae FA; Boussioutas A; Poplawski NK; Parry S; Arnold J; Young JP; Casey G; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Potter JD; DeRycke M; Lindor NM; Thibodeau SN; Baron JA; Win AK; Hopper JL; Jenkins MA; Buchanan DD;
    BMJ Open; 2016 Feb; 6(2):e010293. PubMed ID: 26895986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
    Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
    BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
    Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
    BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Founder mutation in Lynch syndrome].
    Cajal AR; Piñero TA; Verzura A; Santino JP; Solano AR; Kalfayan PG; Ferro A; Vaccaro C
    Medicina (B Aires); 2016; 76(3):180-2. PubMed ID: 27295708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplicon-based NGS test for assessing MLH1 promoter methylation and its correlation with BRAF mutation in colorectal cancer patients.
    da Silva SIO; Domingos TA; Kupper BEC; De Brot L; Aguiar Junior S; Carraro DM; Torrezan GT
    Exp Mol Pathol; 2023 Apr; 130():104855. PubMed ID: 36736685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PMS2 involvement in patients suspected of Lynch syndrome.
    Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
    Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique
    Serra S; Capo-Chichi JM; McCarthy AJ; Sabatini P; Chetty R
    J Clin Pathol; 2020 May; 73(5):291-295. PubMed ID: 31649038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLH1 epimutation is a rare mechanism for Lynch syndrome: A case report and review of the literature.
    Zyla R; Graham T; Aronson M; Velsher L; Mrkonjic M; Turashvili G
    Genes Chromosomes Cancer; 2021 Sep; 60(9):635-639. PubMed ID: 33934415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lynch syndrome-related small intestinal adenocarcinomas.
    Jun SY; Lee EJ; Kim MJ; Chun SM; Bae YK; Hong SU; Choi J; Kim JM; Jang KT; Kim JY; Kim GI; Jung SJ; Yoon G; Hong SM
    Oncotarget; 2017 Mar; 8(13):21483-21500. PubMed ID: 28206961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
    Malander S; Rambech E; Kristoffersson U; Halvarsson B; Ridderheim M; Borg A; Nilbert M
    Gynecol Oncol; 2006 May; 101(2):238-43. PubMed ID: 16360201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.